Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis
NCT ID: NCT01578811
Last Updated: 2013-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
102 participants
INTERVENTIONAL
2011-08-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis
NCT02353039
Effect of H. Pylori Eradication on Alleviating Symptoms in Functional Dyspepsia Patients
NCT05786807
The Effact of Helicobacter Hylori Eradication on the Development of Gastric Mucosa Pathology
NCT04029441
Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients With Gastritis
NCT03184415
To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient
NCT05163756
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
Dosage
SK-MS10 160mg t.i.d
SK-MS10
Dosage
SK-MS10 320mg t.i.d
SK-MS10
Dosage
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Dosage
SK-MS10
Dosage
SK-MS10
Dosage
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients who voluntarily signed written informed consent may participate in the study.
Exclusion Criteria
2. Patients have gastric ulcer, duodenal ulcer and GERD.
3. Use of any proton pump inhibitor, H2-receptor antagonist, muscarine receptor antagonist and gastrin receptor antagonist within 2 weeks before initiating study drug therapy
4. Patients requiring corticosteroid therapy
5. Severe neurological or psychological disease
6. History of allergic reaction to the medications used in this study
7. Use of other investigational drugs within 30 days prior to the study.
8. Patients that investigators consider ineligible for this study
19 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SK Chemicals Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SKChemicals
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SK-MS10_GID_II_2010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.